Who We Are

At Tozho, we are redefining what’s possible in regenerative medicine through the development of engineered extracellular vesicle (EV) therapies. Our platform merges advanced cellular biology, immune engineering, and scalable biomanufacturing to deliver targeted, cell-free treatments for chronic wounds and tissue repair.

Rooted in scientific rigor, our technology centers on mesenchymal stem cell–derived EVs that are bioengineered to address critical limitations in wound healing. By encapsulating therapeutic enzymes like thymidine phosphorylase and decorating the vesicle surface with CD47—a “don’t-eat-me” immune signal—Tozho’s EVs promote angiogenesis while resisting premature clearance by the immune system. This allows for prolonged therapeutic activity in inflammatory microenvironments where traditional therapies fall short.

To support clinical translation, we’ve developed a proprietary chitin nanoparticle–based isolation process that dramatically increases EV purity and yield, while remaining GMP-adaptable and cost-efficient. Our culture system leverages serum-free media enriched with microalgal extracts, boosting MSC proliferation and vesicle output in a sustainable, serum-free model.

Tozho exists at the intersection of innovation and impact. Our mission is not only to push the boundaries of regenerative science but to create therapies that are accessible, scalable, and transformative for patients suffering from chronic, non-healing wounds.

We are scientists, engineers, and clinicians working toward a singular goal: to unlock the healing power of extracellular vesicles and deliver smarter, more enduring solutions for human health.